RT Journal Article
SR Electronic
T1 Detection of SARS-CoV-2 from raw patient samples by coupled high temperature reverse transcription and amplification
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.19.20103150
DO 10.1101/2020.05.19.20103150
A1 Johannes W. P. Kuiper
A1 Timo Baade
A1 Marcel Kremer
A1 Ramon Kranaster
A1 Linda Irmisch
A1 Marcus Schuchmann
A1 Johannes Zander
A1 Andreas Marx
A1 Christof R. Hauck
YR 2020
UL http://medrxiv.org/content/early/2020/05/22/2020.05.19.20103150.abstract
AB The SARS-CoV-2 beta coronavirus is spreading globally with unprecedented consequences for modern societies. The early detection of infected individuals is a prerequisite for all strategies aiming to contain the virus. Currently, purification of RNA from patient samples followed by RT-PCR is the gold standard to assess the presence of this single-strand RNA virus. However, these procedures are time consuming, require continuous supply of specialized reagents, and are prohibitively expensive in resource-poor settings. Here, we report an improved nucleic-acid-based approach to detect SARS-CoV-2, which alleviates the need to purify RNA, reduces handling steps, minimizes costs, and allows evaluation by non-specialized equipment. The use of unprocessed swap samples and the ability to detect as little as three viral genome equivalents is enabled by employing a heat-stable RNA- and DNA-dependent DNA polymerase, which performs the double task of stringent reverse transcription of RNA at elevated temperatures as well as PCR amplification of a SARS-CoV-2 specific target gene. As results are obtained within 2 hours and can be read-out by a hand-held LED-screen, this novel protocol will be of particular importance for large-scale virus surveillance in economically constrained settings.Competing Interest StatementAM, RK are founders of and employed by myPOLS Biotec GmbH, manufacturer of Volcano3G polymerase used in this manuscript. All other authors declare that they have no conflict of interest. Clinical TrialDRKS00021578 (German Clinical trials Register)Funding StatementTB acknowledges support from the Konstanz Research School Chemical Biology (KoRS-CB) and AM acknowledges support by the German Research Foundation (DFG) within SPP 1784.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll original data are included in the manuscript